Results 21 to 30 of about 4,025 (198)
Novel Fidaxomicin Antibiotics through Site-Selective Catalysis [PDF]
, 2020 Fidaxomicin (FDX) is a marketed antibiotic for the treatment Clostridium difficile infections (CDI). Although showing interesting antibacterial properties against many Gram-positive bacteria, the application of this antibiotic is currently limited to ...
Daniel, Schäfle +4 more
core +1 more source
Semisynthetic Analogs of the Antibiotic Fidaxomicin – Design, Synthesis, and Biological Evaluation [PDF]
, 2020 The glycoslated macrocyclic antibiotic fidaxomicin (1, tiacumicin B, lipiarmycin A3) displays good to excellent activity against Gram-positive bacteria and was approved for the treatment of Clostridium difficile infections (CDI).
Regina, Berg +9 more
core +1 more source
Novel fidaxomicin antibiotics through site-selective catalysis [PDF]
, 2021 Fidaxomicin (FDX) is a marketed antibiotic for the treatment of Clostridioides difficile infections (CDI). Fidaxomicin displays antibacterial properties against many Gram-positive bacteria, yet the application of this antibiotic is currently limited to ...
Schäfle, Daniel +4 more
core +1 more source
Gut Pathogens, 2022 The anaerobic, gastrointestinal pathogen Clostridioides difficile can cause severe forms of enterocolitis which is mainly mediated by the toxins it produces.
Madita Brauer +5 more
doaj +1 more source
Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection [PDF]
, 2014 OBJECTIVES: Fidaxomicin was non-inferior to vancomycin with respect to clinical cure rates in the treatment of Clostridium difficile infections (CDIs) in two Phase III trials, but was associated with significantly fewer recurrences than vancomycin.
Cornely, Oliver A. +5 more
core +1 more source
Fidaxomicin to prevent recurrent
, 2023 IMPORTANCE: Recent changes in guidelines for managing OBJECTIVE: To estimate the net cost of first-line fidaxomicin compared to vancomycin in the American and Canadian healthcare systems and to estimate the price points at which fidaxomicin would become ...
Spellberg, Brad +7 more
core +1 more source
GAIMS Journal of Medical Sciences, 2022 Introduction We searched the databases to include randomized studies evaluating the effect of fidaxomicin on cure and recurrence rate in Clostridium difficile infection (CDI). Due to its increasing severity and recurrence rates, decrease in cure rates,
Hiral N Golakiya +2 more
doaj +1 more source
Visualization of fidaxomicin association with the exosporium layer of Clostridioides difficile spores [PDF]
, 2021 Indexación ScopusBackground: Fidaxomicin has novel pharmacologic effects on C. difficile spore formation including outgrowth inhibition and persistent spore attachment. However, the mechanism of fidaxomicin attachment on spores has not undergone rigorous
Garey, K.W. +9 more
core +1 more source
Antimicrobial Activities of Fidaxomicin [PDF]
Clinical Infectious Diseases, 2012 Fidaxomicin is bactericidal against Clostridium difficile. The combined results of 8 in vitro studies of 1323 C. difficile isolates showed the minimum inhibitory concentration (MIC) range of fidaxomicin to be ≤ 0.001-1 μg/mL, with a maximum MIC for inhibition of 90% of organisms (MIC(90)) of 0.5 μg/mL.
Goldstein, Ellie J. C. +2 more
openaire +2 more sources
A Novel Treatment Approach to Treatment-Resistant, Recurrent Clostridium difficile
Case Reports in Gastroenterology, 2022 A 36-year-old male with a previous medical history of persistent Clostridium difficile presented to clinic for evaluation of diarrheal symptoms intermittently for the last 2 years. He reported recurrent episodes of C. difficile that initially began after
Megha Gangadhar +2 more
doaj +1 more source